Business
Earth Science Tech, Inc. Announces New Agreement with a Private Laboratory to Develop and Commercialize MSN-2 Medical Device
Earth Science Tech, Inc. Announces New Agreement with a Private Laboratory to Develop and Commercialize MSN-2 Medical Device.
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\n Doral, FL,, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) (\"ETST\" or, the “Company\"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device R&D, is pleased to announce the company has signed a deal with Laboratories BNK Canada, Inc. (http://www.labobnk.com/), for clinical studies related to the MSN-2 Medical Device. BNK is a private laboratory, which will conduct the clinical studies required to add more tests to the company’s MSN-2 medical device-related services.\n ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea. In the near future, ETST will add testing for trichomoniasis, and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. Both are highly infectious sexually transmitted infections (STI). These additions will help the company create sales opportunities in new markets. BNK brings a team of professional scientists from the pharmaceutical, clinical research, and even hospital settings. BNK will assist ETST in the design, development, and validation of testing methods that meet all regulatory requirements. In addition, BNK will assist with the determination and development of study-specific tests for ETST clinical projects and bring expertise in clinical research project management to ensure that all trials run smoothly. This expertise will help the company maintain efficiency and reduce R&D costs. “We are on the cusp of making tremendous progress in our clinical trial efforts,” said Dr. Michel Aubé, CEO and CSO of ETST. He continued, “Our partnership with BNK will allow us to leverage the expertise of R&D veterans of many years, which will help us move more quickly, develop more products, cut costs, and ultimately, treat more patients.” Chlamydia and other sexually transmitted infections (STIs) often have permanent consequences for patients, and damage society at large. The World Health Organization now recommends that all pregnant women be tested for chlamydia, which has created a very large testing market. This partnership with BNK is expected to help ETST increase its total attainable market in this sp...